Your Partner in Pharmaceutical Development
PBI is dedicated to the development of therapeutics for the treatment of life-threatening diseases. The Company’s immuno-oncology PB307 biologic is designed to promote and harness the body’s own immune system to destroy cancer cells. PB307 has been demonstrated in animal models to show dramatically increased tumor infiltrating lymphocytes (TILs) in tumor, significantly decreased immunosuppressive components in tumor, and tumor microenvironment modulation for enhancing cancer immunotherapy.
PB307 is an immuno-oncology drug, a formula developed leveraging years of research and development from the immune responses in cancer therapy. PB307 is designed to inhibit the growth of cancer cells and to strengthen the body’s immune system to promote a sustained and enhanced immune response to attack cancers without side effects. PB307 target indications include pancreatic, breast, colorectal, gastric, brain, liver, ovarian, lung and other cancers.
PB121 is an immune-oncology therapeutic. The improved PB121 cytokine formulation is developed to specifically activate NK cells and T effector cells as well as to overcome immunosuppressive components of the tumor microenvironment.
PB718 is developed for drug addiction treatment. This anti-addiction product is designed to prevent people who have certain drug addictions (e.g., opioids) from taking them again. For opioid addiction, it works in the brain to reduce and further prevent opiate effects. PB718 is formulated to reduce the symptoms of opiate withdrawal and minimize patient discomfort during the detox duration. PB718 is a novel next generation therapeutic providing solutions to treat both pain and addiction.
PB922 is an anti-inflammatory biological product. PB922 formulation is an enhanced biological system consisting of regulation of cytokines production and T cell proliferation. It is developed for the treatment of autoimmune diseases, including multiple sclerosis, Crohn’s disease, ulcerative colitis, and rheumatoid arthritis.
PB844 is a specially formulated naturally occurring biologic and is developed for the treatment of neurologic disorders and neurodegenerative diseases.
PB1018 is an immunotherapeutic biologic being developed for the treatment of viral infections.
PBI utilizes BioSynersys™ to develop new generation Synergy PEG-enhanced drugs from the existing biological drugs.
PB1103 is the synergy interferon-alfa developed based on BioSynersys™ for the treatment of cancers, blood disorders and viral diseases. Synergy interferon-alfa can enhance a patient’s immune response to cancer cells and may also inhibit the growth of cancer cells. PB1103 is expected to be an effective biological therapeutics for the treatment of various cancers, including kidney, melanoma, Kaposi sarcoma, hairy cell leukemia (HCL), myeloid leukemia (CML) and hematologic cancers.
Also, synergy interferon-alfa provides increased and sustained antiviral activity plus synergistically enhanced pharmacological properties and has been demonstrated to be superior to the commercial Pegylated interferon-alfa. PB1103 is a new generation interferon therapeutic for viral infections, including hepatitis B and hepatitis C.